External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>IPCA Labs’ (IPCA) brand-building strength is poised to drive outperformance against IPM growth, with synergies from Unichem integration further accelerating earnings</li><li>Our positive outlook is based on several key factors: First, IPCA’s brand-building and new product launches will support sustained sales growth</li><li>Additionally, the company’s strong positioning in acute and chronic therapies (CVS, anti-diabetics, CNS, and urology)—will enable it to outperform IPM growth</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

IPCA Labs’ (IPCA) brand-building strength is poised to drive outperformance against IPM growth, with synergies from Unichem integration further accelerating earningsOur positive outlook is based on several key factors: First, IPCA’s brand-building and new product launches will support sustained sales growthAdditionally, the company’s strong positioning in acute and chronic therapies (CVS, anti-diabetics, CNS, and urology)—will enable it to outperform IPM growthContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IPCA Laboratories(보도 시작): 인도의 꾸준한 성장, 수출은 Unichem Synergy에 의존합니다. 매수

Ipca Laboratories

IPCA Laboratories(보도 시작): 인도의 꾸준한 성장, 수출은 Unichem Synergy에 의존합니다. 매수